Arvinas to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced its participation in two major investor conferences. The company will be present at the Guggenheim Securities Healthcare Innovation Conference on November 13, where Chief Medical Officer Noah Berkowitz and Chief Business Officer Randy Teel will join a fireside chat. Additionally, on November 19, Berkowitz and Chief Financial Officer Andrew Saik will participate in a fireside chat at the Jefferies London Healthcare Conference. Live audio webcasts of both presentations will be accessible through the company's website and dedicated links.

News Market Reaction

-0.37%

1 alert

-0.37% News Effect

On the day this news was published, ARVN declined 0.37%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

• Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13.
  • Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
    
• Jefferies London Healthcare Conference on Tuesday, November 19.
  • Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

What investor conferences will Arvinas (ARVN) attend in November 2024?

Arvinas will participate in the Guggenheim Securities Healthcare Innovation Conference on November 13 and the Jefferies London Healthcare Conference on November 19, 2024.

Who will represent Arvinas (ARVN) at the Guggenheim Securities Healthcare Conference?

Chief Medical Officer Noah Berkowitz and Chief Business Officer Randy Teel will represent Arvinas at the Guggenheim Securities Healthcare Conference.

How can investors access Arvinas (ARVN) conference presentations in November 2024?

Investors can access live audio webcasts of the presentations through dedicated links and the Events and Presentations section of Arvinas's website.

Which executives will participate in Arvinas (ARVN) Jefferies London Healthcare Conference?

Chief Medical Officer Noah Berkowitz and Chief Financial Officer Andrew Saik will participate in the Jefferies London Healthcare Conference.